RT Journal Article
T1 Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
A1 Mielke, Orell
A1 Bril, Vera
A1 Cornblath, David R
A1 Lawo, John-Philip
A1 van Geloven, Nan
A1 Hartung, Hans-Peter
A1 Lewis, Richard A
A1 Merkies, Ingemar S J
A1 Sobue, Gen
A1 Durn, Billie
A1 Shebl, Amgad
A1 van Schaik, Ivo N
A1 PATH study group, 
K1 Privigen
K1 chronic inflammatory demyelinating polyneuropathy (CIDP)
K1 inflammatory neuropathy cause and treatment (INCAT)
K1 intravenous immunoglobulin (IVIG)
K1 polyneuropathy and treatment with Hizentra (PATH)
AB In patients with chronic inflammatory demyelinating polyneuropathy (CIDP), intravenous immunoglobulin (IVIG) is recommended to be periodically reduced to assess the need for ongoing therapy. However, little is known about the effectiveness of restabilization with IVIG in patients who worsen after IVIG withdrawal. In the Polyneuropathy And Treatment with Hizentra (PATH) study, the pre-randomization period included sudden stopping of IVIG followed by 12 weeks of observation. Those deteriorating were then restabilized with IVIG. Of 245 subjects who stopped IVIG, 28 did not show signs of clinical deterioration within 12 weeks. Two hundred and seven received IVIG restabilization with an induction dose of 2 g/kg bodyweight (bw) IgPro10 (Privigen, CSL Behring, King of Prussia, Pennsylvania) and maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks. Signs of clinical improvement were seen in almost all (n = 188; 91%) subjects. During IVIG restabilization, 35 subjects either did not show CIDP stability (n = 21, analyzed as n = 22 as an additional subject was randomized in error) or withdrew for other reasons (n = 14). Of the 22 subjects who did not achieve clinical stability, follow-up information in 16 subjects after an additional 4 weeks was obtained. Nine subjects were reported to have improved, leaving a maximum of 27 subjects (13%) who either showed no signs of clinical improvement during the restabilization phase and 4 weeks post-study or withdrew for other reasons. In conclusion, sudden IVIG withdrawal was effective in detecting ongoing immunoglobulin G dependency with a small risk for subjects not returning to their baseline 17 weeks after withdrawal.
YR 2019
FD 2019-03-01
LK http://hdl.handle.net/10668/13448
UL http://hdl.handle.net/10668/13448
LA en
DS RISalud
RD Apr 11, 2025